Ceva restructures shareholding to boost global innovation in animal health

FRANCE – Ceva Animal Health, a leading global animal health company, has restructured its capital and opened it to new investors, reaffirming its independence and commitment to innovation in the global veterinary sector.

Announced this week, the company confirmed that all existing stakeholders—its long-term partners, known as the “Friends of Ceva,” and financial investors led by Singapore-based Temasek—have renewed their commitments in the latest funding round. 

This sixth round also welcomed new strategic investors, including the Mérieux Institute and French healthcare-focused fund ARCHIMED, further strengthening Ceva’s capital base.

“I am delighted to see that in this new round of financing, the management’s participation, supported by the ‘Friends of Ceva’, is being strengthened alongside our historic financial investors and new entrants,” said Marc Prikazsky, Ceva’s chairman and CEO. 

“At Ceva, we are convinced that we must continue to create bridges between different health sectors to protect the health of ecosystems and humans as well as global food security.”

Under Prikazsky’s leadership, Ceva’s management team has increased its shareholding and retained the majority of voting rights, ensuring the company remains independent while positioning itself for future growth.

The new capital structure includes significant investments from the Bettencourt-Meyers family via Téthys Invest and the Mérieux Institute, which joined forces with Mérieux Equity Partners. PSP Investments, a Canadian pension fund and long-time Ceva partner, also increased its stake. 

Additional investors in the “Friends of Ceva” group include Sofiprotéol, Mitsui & Co., the Klocke family, and several local investment entities.

Founded in 1999, Ceva has rapidly expanded its global footprint, now operating in 47 countries with over 7,000 employees. 

The company reached revenues of €1.77 (US$1.93) billion in 2023, having grown its income fourteenfold in just over two decades. 

It has become a global leader in vaccination and preventive medicine, delivering solutions to veterinarians, livestock producers, and pet owners worldwide.

Pioneering strides in vaccine production 

Ceva was the first veterinary firm to commercialise a nucleotide vaccine and continues to invest in gene therapy for companion animals, cementing its reputation as a trailblazer in veterinary science.

New investor ARCHIMED, led by veterinarian Denis Ribon, brings specialised healthcare sector expertise and a mission to help Ceva expand internationally and accelerate its R&D programs. 

“ARCHIMED’s entry reinforces our long-term strategy to drive global innovation and meet pressing animal health challenges,” said a Ceva spokesperson.

With the world facing growing threats from emerging zoonotic diseases and rising demand for sustainable food production, Ceva’s renewed shareholder base is expected to power the next phase of innovation in animal and ecosystem health.

Sign up HERE to receive our email newsletters with the latest news updates and insights from Africa and the World, and follow us on our WhatsApp channel for updates.